[1] |
World Health Organization. World Malaria Report 2021[R]. Geneva: World Health Organization, 2021.
|
[2] |
Zhang L, Feng J, Tu H, et al. Malaria epidemiology in China in 2020[J]. Chin J Parasitol Parasit Dis, 2021, 39(2): 195-199. (in Chinese)
|
|
(张丽, 丰俊, 涂宏, 等. 2020年全国疟疾疫情分析[J]. 中国寄生虫学与寄生虫病杂志, 2021, 39(2): 195-199.)
|
[3] |
Feng J, Zhou SS. From control to elimination: the historical retrospect of malaria control and prevention in China[J]. Chin J Parasitol Parasit Dis, 2019, 37(5): 505-513. (in Chinese)
|
|
(丰俊, 周水森. 从控制走向消除: 我国疟疾防控的历史回顾[J]. 中国寄生虫学与寄生虫病杂志, 2019, 37(5): 505-513.)
|
[4] |
Wang J, Shen Y, Li Y, et al. Recent progress in immune checkpoint molecules in Plasmodium infection and immunity[J]. Chin J Parasitol Parasit Dis, 2019, 37(4): 472-480. (in Chinese)
|
|
(王军, 沈燕, 李悦, 等. 免疫检查点分子调控在疟原虫感染与免疫中的研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2019, 37(4): 472-480.)
|
[5] |
Baldwin MR, Li X, Hanada T, et al. Merozoite surface protein 1 recognition of host glycophorin a mediates malaria parasite invasion of red blood cells[J]. Blood, 2015, 125(17): 2704-2711.
doi: 10.1182/blood-2014-11-611707
|
[6] |
Holder AA. The precursor to major merozoite surface antigens: structure and role in immunity[J]. Prog Allergy, 1988, 41: 72-97.
pmid: 3043424
|
[7] |
Blackman MJ, Holder AA. Secondary processing of the Plasmodium falciparum merozoite surface protein-1 (MSP1) by a calcium-dependent membrane-bound serine protease: shedding of MSP133 as a noncovalently associated complex with other fragments of the MSP1[J]. Mol Biochem Parasitol, 1992, 50(2): 307-315.
doi: 10.1016/0166-6851(92)90228-C
|
[8] |
Thái TL, Jun H, Lee J, et al. Genetic diversity of merozoite surface protein-1 C-terminal 42 kDa of Plasmodium falciparum (PfMSP-142) may be greater than previously known in global isolates[J]. Parasit Vectors, 2018, 11(1): 455.
doi: 10.1186/s13071-018-3027-x
pmid: 30081943
|
[9] |
Soares IS, Levitus G, Souza JM, et al. Acquired immune responses to the N- and C-terminal regions of Plasmodium vivax merozoite surface protein 1 in individuals exposed to malaria[J]. Infect Immun, 1997, 65(5): 1606-1614.
doi: 10.1128/iai.65.5.1606-1614.1997
pmid: 9125537
|
[10] |
Versiani FG, Almeida ME, Mariuba LA, et al. N-terminal Plasmodium vivax merozoite surface protein-1, a potential subunit for malaria vivax vaccine[J]. Clin Dev Immunol, 2013, 2013: 965841.
|
[11] |
Elizardez YB, Fotoran WL, Junior AJG, et al. Recombinant proteins of Plasmodium malariae merozoite surface protein 1 (PmMSP1): testing immunogenicity in the BALB/c model and potential use as diagnostic tool[J]. PLoS One, 2019, 14(7): e0219629.
doi: 10.1371/journal.pone.0219629
|
[12] |
Chu R, Zhang X, Xu S, et al. Limited genetic diversity of N-terminal of merozoite surface protein-1 (MSP-1) in Plasmodium ovale curtisi and P. ovale wallikeri imported from Africa to China[J]. Parasit Vectors, 2018, 11(1): 596.
doi: 10.1186/s13071-018-3174-0
|
[13] |
Chen J, Liu YB, Tang F, et al. Polymorphism analysis of K13 gene of Plasmodium ovale isolates from Africa[J]. Chin J Parasitol Parasit Dis, 2019, 37(2): 167-172. (in Chinese)
|
|
(陈静, 刘耀宝, 唐凤, 等. 卵形疟原虫非洲分离株K13基因的多态性分析[J]. 中国寄生虫学与寄生虫病杂志, 2019, 37(2): 167-172.)
|
[14] |
Peng H, Wang YY, Zhou AG, et al. Enhancement of immunogenicity of Plasmodium falciparum antigens by combination of CpG ODN protein with montanide ISA720 adjuvant[J]. Chin Trop Med, 2010, 10(7): 786-788. (in Chinese)
|
|
(彭恒, 王颖玉, 周爱国, 等. ISA720与CpG联合佐剂增强恶性疟原虫抗原的免疫原性[J]. 中国热带医学, 2010, 10(7): 786-788.)
|
[15] |
Mamillapalli A, Sunil S, Diwan SS, et al. Polymorphism and epitope sharing between the alleles of merozoite surface protein-1 of Plasmodium falciparum among Indian isolates[J]. Malar J, 2007, 6: 95.
doi: 10.1186/1475-2875-6-95
|
[16] |
Takala SL, Coulibaly D, Thera MA,, et al. Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development[J]. Sci Transl Med, 2009, 1(2): 2ra5.
|
[17] |
Duffy PE, Patrick GJ. Malaria vaccines since 2000: progress, priorities, products[J]. Npj Vaccines, 2020, 5(1): 1-9.
doi: 10.1038/s41541-019-0151-3
|
[18] |
Read AF, Baigent SJ, Powers C, et al. Imperfect vaccination can enhance the transmission of highly virulent pathogens[J]. PLoS Biol, 2015, 13(7): e1002198.
doi: 10.1371/journal.pbio.1002198
|
[19] |
Qian F, Xu HJ. Malaria conjugate vaccine[J]. Chin J Parasitol Parasit Dis, 2012, 30(5): 393-395, 400. (in Chinese)
|
|
(钱锋, 徐沪济. 疟疾偶联疫苗[J]. 中国寄生虫学与寄生虫病杂志, 2012, 30(5): 393-395, 400.)
|
[20] |
Chen JT, Li J, Zha GC, et al. Genetic diversity and allele frequencies of Plasmodium falciparum msp1 and msp2 in parasite isolates from Bioko Island, Equatorial Guinea[J]. Malar J, 2018, 17: 458.
doi: 10.1186/s12936-018-2611-z
|
[21] |
Soares LA, Evangelista J, Orlandi PP, et al. Genetic diversity of MSP1 Block 2 of Plasmodium vivax isolates from Manaus (central Brazilian Amazon)[J]. J Immunol Res, 2014, 2014: 671050.
|
[22] |
Noranate N, Prugnolle F, Jouin H, et al. Population diversity and antibody selective pressure to Plasmodium falciparum MSP1 block 2 locus in an African malaria-endemic setting[J]. BMC Microbiol, 2009, 9: 219.
doi: 10.1186/1471-2180-9-219
|
[23] |
Cheng Y, Wang B, Sattabongkot J, et al. Immunogenicity and antigenicity of Plasmodium vivax merozoite surface protein 10[J]. Parasitol Res, 2014, 113(7): 2559-2568.
doi: 10.1007/s00436-014-3907-8
pmid: 24764159
|